Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Alnylam

    - PMLiVE

    The power of representation, innovation and trust in rare disease clinical trials

    By Carol Pitcher-Towner

    - PMLiVE

    Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease

    The committee has recommended the drug for both wild type and hereditary ATTR-CM

    - PMLiVE

    Alnylam scores EU approval for RNAi drug Givlaari

    Company says it will work towards value-based agreements for the drug

    - PMLiVE

    Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

    Plans to file for approval in US and Europe in early 2020

    - PMLiVE

    FDA clears Alnylam’s second RNAi drug for rare disease

    Second drug in the class to be cleared by regulatory authority

    - PMLiVE

    ACPs to lead gene therapies in haemophilia market growth

    New therapies to hit existing players

    - PMLiVE

    Alnylam gains key NICE approval for Onpattro

    Important milestone for company's first product

    - PMLiVE

    Speedy approval for Pfizer’s Onpattro rival

    Approved in two different formulations

    - PMLiVE

    Akcea steals march on Alnylam with NICE approval

    Advantage to Tegsedi over Onpattro

    - PMLiVE

    Alnylam swaps Sanofi for Regeneron as R&D partner

    Novel alliance between two biotechs

    - PMLiVE

    NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

    Room for manoeuvre after initial rejection

    - PMLiVE

    Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links